DOP2023000143A - Antagonistas de gitr y métodos de uso de los mismos - Google Patents

Antagonistas de gitr y métodos de uso de los mismos

Info

Publication number
DOP2023000143A
DOP2023000143A DO2023000143A DO2023000143A DOP2023000143A DO P2023000143 A DOP2023000143 A DO P2023000143A DO 2023000143 A DO2023000143 A DO 2023000143A DO 2023000143 A DO2023000143 A DO 2023000143A DO P2023000143 A DOP2023000143 A DO P2023000143A
Authority
DO
Dominican Republic
Prior art keywords
methods
compounds
gitr antagonists
gitr
antagonists
Prior art date
Application number
DO2023000143A
Other languages
English (en)
Inventor
Lynn Lee Stacey
Francis Cain Paul
Ann Lacerte Melinda
Verdino Petra
Andrew Wortinger Mark
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2023000143A publication Critical patent/DOP2023000143A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente descripción se refiere a compuestos que se unen al GITR humano, composiciones farmacéuticas que comprenden tales compuestos y métodos de uso de tales compuestos.
DO2023000143A 2021-02-02 2023-07-26 Antagonistas de gitr y métodos de uso de los mismos DOP2023000143A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144732P 2021-02-02 2021-02-02
US202263297968P 2022-01-10 2022-01-10
PCT/US2022/014752 WO2022169766A1 (en) 2021-02-02 2022-02-01 Gitr antagonists and methods of using the same

Publications (1)

Publication Number Publication Date
DOP2023000143A true DOP2023000143A (es) 2023-09-15

Family

ID=80787518

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2023000143A DOP2023000143A (es) 2021-02-02 2023-07-26 Antagonistas de gitr y métodos de uso de los mismos

Country Status (15)

Country Link
US (1) US11859005B2 (es)
EP (1) EP4288097A1 (es)
JP (1) JP2024505563A (es)
KR (1) KR20230122171A (es)
AU (1) AU2022216230A1 (es)
CA (1) CA3205852A1 (es)
CL (1) CL2023002288A1 (es)
CO (1) CO2023009885A2 (es)
CR (1) CR20230365A (es)
DO (1) DOP2023000143A (es)
EC (1) ECSP23058279A (es)
IL (1) IL304434A (es)
MX (1) MX2023009007A (es)
TW (1) TW202246334A (es)
WO (1) WO2022169766A1 (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
KR101566538B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ17 세포 전환용 에피토프 및 이의 용도
NZ726513A (en) 2014-05-28 2023-07-28 Memorial Sloan Kettering Cancer Center Anti-gitr antibodies and methods of use thereof
CA2997444A1 (en) * 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
CA3007233A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
WO2017096276A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
CA3007022A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
CA3016894A1 (en) * 2016-03-08 2017-09-14 Janssen Biotech, Inc. Gitr antibodies, methods, and uses
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
CN110475787A (zh) * 2017-01-27 2019-11-19 超人壹有限公司 结合剂
CN110431152A (zh) * 2017-03-03 2019-11-08 雷纳神经科学公司 抗gitr抗体及其使用方法
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
CA3056816A1 (en) * 2017-03-31 2018-10-04 Zymeworks Inc. Tumor antigen presentation inducer constructs and uses thereof

Also Published As

Publication number Publication date
ECSP23058279A (es) 2023-09-29
EP4288097A1 (en) 2023-12-13
US11859005B2 (en) 2024-01-02
CR20230365A (es) 2023-09-08
IL304434A (en) 2023-09-01
CL2023002288A1 (es) 2024-02-02
KR20230122171A (ko) 2023-08-22
WO2022169766A1 (en) 2022-08-11
JP2024505563A (ja) 2024-02-06
CA3205852A1 (en) 2022-08-11
US20220251227A1 (en) 2022-08-11
CO2023009885A2 (es) 2023-08-09
AU2022216230A1 (en) 2023-07-20
MX2023009007A (es) 2023-08-08
TW202246334A (zh) 2022-12-01

Similar Documents

Publication Publication Date Title
CO2022003782A2 (es) Inhibidores de kras g12d
CO2020007244A2 (es) Inhibidores de kras g12c
CO2020005887A2 (es) Compuestos policíclicos como inhibidores alostéricos de shp2
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
ECSP22012826A (es) Inhibidores de parp1
CL2019000793A1 (es) Moduladores de calpaínas y usos terapéuticos de los mismos.
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
CO2021016018A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
ECSP18066138A (es) Inhibidores de la proteína quinasa 1 que interactua con el receptor
DOP2020000021A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anti-cd39
CO2021016015A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
UY37410A (es) Antagonistas de trpv4
ECSP077316A (es) Compuestos imidazo-3-il-amina bicíclicos sustituidos
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
ECSP21026339A (es) Anticuerpos anti–hla–g, composiciones que comprenden anticuerpos anti–hla–g y métodos de uso de anticuerpos anti–hla–g
CL2022000201A1 (es) Inhibidores tricíclicos de kars dependientes de akr1c3
BR112015011760A2 (pt) composto, uso do composto, e uso de uma composição farmacêutica
CO2022009510A2 (es) Compuestos activos frente a receptores nucleares
CL2020002680A1 (es) Anticuerpos para radionúclidos quelados
BR112015026388A8 (pt) uso de um composto de epoxi-tigliane, composto e composição farmacêutica
BR112016026660A2 (pt) ?produto extemporâneo para cuidados cosméticos e/ou dermatológicos, e, kit de preparação extemporânea de uma composição cosmética e/ou dermatológica?
CO2024000890A2 (es) Compuestos de heteroarilo para tratar la enfermedad de huntington
CL2021002837A1 (es) Formas sólidas de un inhibidor de glyt1
UY38759A (es) Tienilhidroxiisoxazolinas y derivados de las mismas
BR112015020820A2 (pt) formulação farmacêutica que contém glicosaminoglicano